{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T16:57:23Z","timestamp":1775321843783,"version":"3.50.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pheochromocytomas (PCCs) and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) with heterogeneous clinical presentations. Given the rarity of PCCs\/PPGLs and the paucity of high-level evidence, therapeutic decisions and treatment sequences vary across institutions. This survey explored current diagnostic practices and treatment patterns among Italian healthcare professionals (HCPs) dedicated to NENs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An online survey was conducted among Italian HCPs, members of the Italian Association for Neuroendocrine Tumors (ITANET). The survey included 33 questions covering diagnosis, genetic counseling, imaging, and treatment approaches. Responses were collected from December 15, 2023, to May 30, 2024, and analyzed using descriptive statistics to identify trends in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We recorded 80\/355 responses from invited HCPs (response rate: 23%). Most HCPs (90%) referred all PCC\/PPGL patients for genetic counseling, with 71% adopting gene panels for syndromes like VHL, MEN2, and familial PPGLs. Functional imaging preferences included <jats:sup>68<\/jats:sup>Ga-DOTA-peptide PET\/CT (38%), <jats:sup>18<\/jats:sup>F-DOPA PET\/CT (26%), and <jats:sup>123<\/jats:sup>I-MIBG scintigraphy (19%). First-line systemic treatments favored somatostatin analogs (39%), clinical trial enrollment (19%), and CVD chemotherapy (15%). Radioligand therapy (RLT) emerged as the preferred second-line treatment (49%). Overall, RLT was perceived as the most effective treatment for achieving objective responses, durable responses, and improving health-related quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clinical wisdom rather than formal evidence and guidelines recommendations appears to guide the management of PCC\/PPGLs among Italian HCPs. International, multi-institutional clinical trials designed to take into account the rarity of PCCs\/PPGLs are needed to generate high-level evidence and provide guidance for standard clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1687570","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:36Z","timestamp":1759119156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Erica","family":"Pietroluongo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella Lucia","family":"Marretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Cives","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Andrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Della Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Dell\u2019Unto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Carli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevena","family":"Mikovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Mascagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Panzuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1515\/enr-2017-0018","article-title":"Pheochromocytoma, diagnosis and treatment: Review of the literature","volume":"51","author":"Farrugia","year":"2017","journal-title":"Endocr Regul"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0258","article-title":"Incidence of pheochromocytoma and paraganglioma varies according to altitude: meta-regression analysis","volume":"184","author":"Leung","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11864-024-01288-z","article-title":"Neuroendocrine tumors: germline genetics and hereditary syndromes","volume":"26","author":"Lauricella","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030354","article-title":"The management of phaeochromocytomas and paragangliomas in the era of precision medicine: where are we now? Evidence-based systemic treatment options and future cluster oriented perspectives","volume":"17","author":"Bracigliano","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 world health organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031450","article-title":"Genetics of pheochromocytomas and paragangliomas determine the therapeutical approach","volume":"23","author":"Sarkadi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101116","article-title":"Management of metastatic pheochromocytomas and paragangliomas: when and what","volume":"51","author":"Sukrithan","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.7.3_pt_2.i18","article-title":"Treatment of Malignant pheochromocytoma with combination chemotherapy","volume":"7","author":"Keiser","year":"1985","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-018-0579-4","article-title":"Continued tumor reduction of metastatic pheochromocytoma\/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy","volume":"38","author":"Jawed","year":"2018","journal-title":"Cell Mol Neurobiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and Malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-024-09830-3","article-title":"The molecular classification of pheochromocytomas and paragangliomas: discovering the genomic and immune landscape of metastatic disease","volume":"35","author":"de Bresser","year":"2024","journal-title":"Endocr Pathol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001251","article-title":"Role of [68Ga]DOTANOC PET\/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study","volume":"41","author":"Singh","year":"2020","journal-title":"Nucl Med Commun"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma: A systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae764","article-title":"Positron emission tomography imaging of pheochromocytoma and paraganglioma-18F-FDOPA vs somatostatin analogues","volume":"110","author":"Ebbehoj","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1687570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:36Z","timestamp":1759119156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1687570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":19,"alternative-id":["10.3389\/fendo.2025.1687570"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1687570","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1687570"}}